Invitae teams up with Alnylam to provide testing for rare gene disorder; shares ahead 4%

|About: Alnylam Pharmaceutical... (ALNY)|By:, SA News Editor

Invitae (NVTA +3.7%) perks up on modestly higher volume in response to its announcement of a partnership with Alnylam (ALNY -0.9%) to provided genetic testing for hereditary ATTR amyloidosis, a rare inherited and life-threatening disorder that causes accumulation of misfolded proteins in cells due to a mutation in the TTR gene.

The service, called Alnylam Act, is aimed at encouraging early genetic testing to aid in the prompt diagnosis of the disease. Financial terms are not disclosed.